Safety of WT1 and PR1 peptide vaccination for patients with myelodysplastic syndrome (MDS)
Phase of Trial: Phase I
Latest Information Update: 31 Jan 2017
At a glance
- Drugs PR1 peptide vaccine (Primary) ; WT1 peptide vaccine (Primary) ; Montanide ISA-51; Sargramostim
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 13 Jun 2007 Status changed from recruiting to completed.
- 06 Nov 2006 New trial record.